Geron trial may resume next year

The Geron Corporation could be cleared to resume its stalled human embryonic stem cell (hESC)-trial for spinal cord injury in the third quarter of next year, linkurl:the company announced today;http://www.geron.com/media/pressview.aspx?id=1195 (October 30). Human embryonic stem cellsImage: Wikimedia commons, Nissim BenvenistyThe Phase I trial, which received clearance from the US Food and Drug Administration (FDA) in January to administer hESC-derived progenitors of neural support tissue into

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
The Geron Corporation could be cleared to resume its stalled human embryonic stem cell (hESC)-trial for spinal cord injury in the third quarter of next year, linkurl:the company announced today;http://www.geron.com/media/pressview.aspx?id=1195 (October 30).
Human embryonic stem cells
Image: Wikimedia commons,
Nissim Benvenisty
The Phase I trial, which received clearance from the US Food and Drug Administration (FDA) in January to administer hESC-derived progenitors of neural support tissue into the spinal cords of patients with severe spinal cord injury, is the first-ever clinical trial of a hESC-based therapy. In August, however, before any patients could receive treatment, the FDA put the trial linkurl:on hold after cysts appeared;http://www.the-scientist.com/blog/display/55950/ in some of the animals that had been given the treatment as part of a preclinical study. Since then, Geron has continued its preclinical study of the treatment, using new markers and assays agreed upon with the FDA, according to their press release. If the study continues to show positive results, the FDA has agreed that the trial could restart in the third quarter of next year. Still, "a great amount of work still needs to be done before any patient is ultimately enrolled into the study," Merriman Curhan Ford analyst Joe Pantginis linkurl:told Reuters.;http://www.reuters.com/article/companyNews/idUSBNG38436220091030
**__Related stories:__***linkurl: Cysts stall stem cell trial?;http://www.the-scientist.com/blog/display/55950/
[27th August 2009]*linkurl:Human stem cell trial on hold;http://www.the-scientist.com/blog/display/55898/
[20th August 2009]*linkurl:FDA OKs stem cell trial;http://www.the-scientist.com/blog/display/55353/
[23rd January 2009]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
A greyscale image of cells dividing.
March 2025, Issue 1

How Do Embryos Know How Fast to Develop

In mammals, intracellular clocks begin to tick within days of fertilization.

View this Issue
Discover the history, mechanics, and potential of PCR.

Become a PCR Pro

Integra Logo
3D rendered cross section of influenza viruses, showing surface proteins on the outside and single stranded RNA inside the virus

Genetic Insights Break Infectious Pathogen Barriers

Thermo Fisher Logo
A photo of sample storage boxes in an ultra-low temperature freezer.

Navigating Cold Storage Solutions

PHCbi logo 
The Immunology of the Brain

The Immunology of the Brain

Products

Zymo Logo

Zymo Research Launches the Quick-16S™ Full-Length Library Prep Kit

BIOVECTRA

BIOVECTRA is Honored with 2025 CDMO Leadership Award for Biologics

Sino Logo

Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV

Stirling Ultracold

Meet the Upright ULT Built for Faster Recovery - Stirling VAULT100™

Stirling Ultracold logo